Search Results

PsychoGenics Inc., the leading contract research organization specializing in central nervous system focused preclinical and translational drug discovery services, is proud to unveil its refreshed corporate identity and brand.

PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997. RO7117997, is an IND-ready Equilibrative Nucleoside Transporter 1 (ENT1) inhibitor discovered in partnership with Roche using the PsychoGenics’ AI-enabled phenotypic screening platforms.

PsychoGenics Inc. and Collaborations Pharmaceuticals, Inc. are pleased to announce that they were awarded a $1million Phase I Small Business Innovation Research grant, to use their combined AI tools to design new drugs for mental health disorders.

IAMA Therapeutics and PsychoGenics Inc. today announced that the companies have entered into an additional services agreement to identify the efficacy of novel drug candidates in preclinical animal models of Dravet syndrome.

PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage biopharmaceutical company Karuna Therapeutics, Inc., (NASDAQ: KRTX) has extended its drug discovery collaboration with the Company aimed at identifying potential novel drug candidates for the treatment of severe neuropsychiatric disorders.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

PsychoGenics Inc. announced that the National Institutes of Health (NIH) has completed the assessment of PsychoGenics data/IT security standards and systems, and gave official authority to operate as a government contractor.

IAMA Therapeutics and PsychoGenics Inc., a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that the companies have entered into a service agreement to identify the efficacy of novel drug candidates in drug-resistant epilepsy.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system